Biotech Values

[upndown1313]

Yes BP is worrisome, I smell extended safety studies... and while HDL raising is not yet validated based on outcomes studies, I disagree it is a meanlingless endpoint. Investors will see a drug that raises HDL and lowers LDL as a true blockbuster and certainly imaging study results will be available much sooner so impact to pps is shorter term, even w/o approval. Very rosy picture except for that "worrisome" BP raising......